Polish Pharma Set to Take on an Even Greater Role in CEE
With a geostrategic location and easy access to both Western Europe and the rest of the emerging Central and Eastern Europe (CEE) region, Poland represents the sixth largest pharma market…
Writing in the January 2026 edition of DIA Global Forum, Mariana Socal and Antonio J. Trujillo from the Johns Hopkins Bloomberg School of Public Health and Rachel Goode of Fresenius Kabi argue that biosimilars could significantly reduce US drug spending…
With a geostrategic location and easy access to both Western Europe and the rest of the emerging Central and Eastern Europe (CEE) region, Poland represents the sixth largest pharma market…
As home to much of Europe’s innovative medicine output and as one of its wealthiest nations per capita, Switzerland has not traditionally been a generic-friendly market. Generics prices are relatively…
Will a new ‘Critical Medicines Act’ go far enough to ensure Europe’s resilience to future health crises? A Continent at Risk The COVID-19 pandemic exposed serious vulnerabilities in the…
At a time when France’s healthcare landscape is being reshaped by regulatory change, market pressure, and shifting patient expectations, Fabrice Ruggeri, Country Manager of Organon France, is steering the affiliate through a new phase of purposeful growth. Under his leadership, Organon France is strengthening its long-standing commitment to women’s health while expanding into new therapeutic areas and building strategic partnerships.…
Christine Baeder, President of USA and LATAM at Apotex, discusses the company’s evolution following private equity investment, its Generics Plus strategy, and the critical role of the US market. She…
Spiro Gavaris, President of Lupin’s US generics business, shares a candid assessment of the shifting dynamics shaping today’s generic and biosimilar landscape. He outlines how Lupin is positioning itself for…
A wave of blockbuster biologics is set to lose patent protection, creating a major inflection point for the biosimilars market in 2025 and beyond. While Europe remains the global leader…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
John Murphy III, President and CEO of the Association for Accessible Medicines (AAM), argues that 2026 represents a pivotal moment for the United States to reclaim leadership in biosimilars. He…
John Murphy, III, president & CEO of the Association for Accessible Medicines (AAM) lays out a stark warning: the very medicines that keep the US healthcare system affordable and functioning…
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…
The leading company in the Egyptian pharma market by volume, the Egyptian International Pharmaceutical Industries Company (EIPICO) is now making a region-first move into biologicals and biosimilars manufacturing to power…
See our Cookie Privacy Policy Here
